STOCK TITAN

Akebia Therapeutics Inc. - AKBA STOCK NEWS

Welcome to our dedicated news page for Akebia Therapeutics (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akebia Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akebia Therapeutics's position in the market.

Rhea-AI Summary
Akebia Therapeutics, Inc. granted six new employees options to purchase 110,000 shares of common stock, following Nasdaq rules. The options have an exercise price of $1.83 per share and vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics receives FDA approval for Vafseo tablets to treat anemia in CKD patients on dialysis. The once-daily oral HIF-PH inhibitor activates the physiologic response to manage anemia, aiming to become a new standard of care. The approval is based on efficacy data from the INNO2VATE program and post-marketing safety data from Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.3%
Tags
-
Rhea-AI Summary
Akebia Therapeutics reported strong financial results for Q4 2023, with potential U.S. approval for vadadustat by March 27, 2024. The company strengthened its balance sheet with term loan financing and ATM proceeds. Auryxia net product revenue for 2023 was $170.3 million, and Akebia introduced new pipeline programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.09%
Tags
Rhea-AI Summary
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) plans to report Q4 and full year 2023 financial results on March 14, 2024. The company will not host a conference call due to the proximity to the PDUFA target action date for vadadustat, a potential treatment for anemia in patients on dialysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences earnings
-
Rhea-AI Summary
Akebia Therapeutics, Inc. granted a newly-hired employee options to purchase 4,000 shares of common stock at $1.58 per share. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% quarterly. This move aligns with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia's common stock, including options for the Chief Commercial Officer and Chief Accounting Officer. The options were granted as an inducement material to each employee entering into employment with Akebia, in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.68 per share, with the stock options vesting over four years. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Akebia Therapeutics, Inc. has closed a loan facility with BlackRock, providing up to $55.0 million of borrowing capacity. The loan will be used to pay down principal outstanding from a previous loan agreement and extends the interest-only period in the event of vadadustat approval by the FDA. The company also has the option to draw down an additional $18.0 million contingent on FDA approval. Akebia's CEO, John P. Butler, expressed satisfaction with the new loan facility and the ongoing support from Pharmakon Advisors, LP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.38%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund brings significant operational, commercial, and strategic leadership experience in the renal and specialty markets. His appointment is crucial as Akebia prepares for the potential vadadustat launch in the U.S. and aims to maximize Auryxia revenue. Prior to joining Akebia, Mr. Grund served as President of Eurofins Transplant Genomics and Chief Commercial Officer of AMAG Pharmaceuticals, with a proven track record of driving revenue growth and operational efficiency improvements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
management
-
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted six newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 29, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.24 per share, vest over four years, and have a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
none
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
Akebia Therapeutics Inc.

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

320.34M
188.22M
2.57%
26.28%
4.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.